WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.There was also no difference between the edoxaban (Savaysa, Daiichi Sankyo) and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function,
Patients treated with the blood thinner edoxaban for six months after a heart valve replacement procedure experienced fewer symptomless blood clots inside the heart valve replacement than patients who.